These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cancer gene therapy using a novel secretable trimeric TRAIL. Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699 [TBL] [Abstract][Full Text] [Related]
4. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Wohlfahrt ME; Beard BC; Lieber A; Kiem HP Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719 [TBL] [Abstract][Full Text] [Related]
5. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Zhao L; Dong A; Gu J; Liu Z; Zhang Y; Zhang W; Wang Y; He L; Qian C; Qian Q; Liu X Cancer Gene Ther; 2006 Nov; 13(11):1011-22. PubMed ID: 16799468 [TBL] [Abstract][Full Text] [Related]
6. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Kagawa S; He C; Gu J; Koch P; Rha SJ; Roth JA; Curley SA; Stephens LC; Fang B Cancer Res; 2001 Apr; 61(8):3330-8. PubMed ID: 11309289 [TBL] [Abstract][Full Text] [Related]
7. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Jacob D; Davis J; Zhu H; Zhang L; Teraishi F; Wu S; Marini FC; Fang B Clin Cancer Res; 2004 May; 10(10):3535-41. PubMed ID: 15161713 [TBL] [Abstract][Full Text] [Related]
8. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and canstatin gene suppression therapy on breast tumor xenograft growth in mice. Wang WB; Zhou YL; Heng DF; Miao CH; Cao YL Breast Cancer Res Treat; 2008 Jul; 110(2):283-95. PubMed ID: 17899369 [TBL] [Abstract][Full Text] [Related]
9. [Anti-tumor effect of eukaryotic expressing plasmid containing soluble tumor necrotic factor-related apoptosis inducing ligand combined with human angiostatin Kringle (1 - 3) genes on human gastric cancer xenografts in nude mice]. Sun W; Jiang Z; Xiang TX; Tao XH; Huang AL; Wang PL Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(12):841-5. PubMed ID: 19595126 [TBL] [Abstract][Full Text] [Related]
10. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy. Zhang Y; Gu J; Zhao L; He L; Qian W; Wang J; Wang Y; Qian Q; Qian C; Wu J; Liu XY Cancer Res; 2006 Apr; 66(8):4291-8. PubMed ID: 16618754 [TBL] [Abstract][Full Text] [Related]
11. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice. Itashiki Y; Harada K; Ferdous T; Yoshida H Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527 [TBL] [Abstract][Full Text] [Related]
12. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy. Kim SM; Oh JH; Park SA; Ryu CH; Lim JY; Kim DS; Chang JW; Oh W; Jeun SS Stem Cells; 2010 Dec; 28(12):2217-28. PubMed ID: 20945331 [TBL] [Abstract][Full Text] [Related]
13. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Lin T; Gu J; Zhang L; Huang X; Stephens LC; Curley SA; Fang B Cancer Res; 2002 Jul; 62(13):3620-5. PubMed ID: 12097263 [TBL] [Abstract][Full Text] [Related]
15. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells. Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708 [TBL] [Abstract][Full Text] [Related]
16. Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus. Zhou W; Zhu H; Chen W; Hu X; Pang X; Zhang J; Huang X; Fang B; He C Cancer Gene Ther; 2011 May; 18(5):336-45. PubMed ID: 21183948 [TBL] [Abstract][Full Text] [Related]
17. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene. Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282 [TBL] [Abstract][Full Text] [Related]
18. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells. Kaliberov S; Stackhouse MA; Kaliberova L; Zhou T; Buchsbaum DJ Gene Ther; 2004 Apr; 11(8):658-67. PubMed ID: 14973547 [TBL] [Abstract][Full Text] [Related]
19. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma. Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790 [TBL] [Abstract][Full Text] [Related]
20. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL. Liu X; Cao X; Wei R; Cai Y; Li H; Gui J; Zhong D; Liu XY; Huang K Cancer Gene Ther; 2012 Jan; 19(1):49-57. PubMed ID: 21979578 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]